Difference between revisions of "Denosumab (Xgeva)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Human IgG2 monoclonal antibody that inhibits RANK ligand (RANKL). RANKL promotes the formation, function, and survival of osteoclasts, which responsible for bone resorption.<ref name="insert">[http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf Denosumab (Xgeva) package insert]</ref><ref>[ | + | Class/mechanism: Human IgG2 monoclonal antibody that inhibits RANK ligand (RANKL). RANKL promotes the formation, function, and survival of osteoclasts, which are responsible for bone resorption.<ref name="insert">[http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf Denosumab (Xgeva) package insert]</ref><ref>[[Media:Denosumab.pdf | Denosumab (Xgeva) package insert (locally hosted backup)]]</ref><ref>[http://www.xgeva.com/ Xgeva manufacturer's website]</ref><ref>[http://www.prolia.com/ Prolia manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 9: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://chemocare.com/chemotherapy/drug-info/denosumab.aspx Denosumab (Xgeva) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/denosumab.aspx Denosumab (Xgeva) patient drug information (Chemocare)]</ref> | ||
| + | *Brief patient counseling information can be found on [http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf#page=13 page 13 of the Denosumab (Xgeva) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/denosumab-patient-drug-information Denosumab (Xgeva) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/denosumab-patient-drug-information Denosumab (Xgeva) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/denosumab-patient-drug-information Denosumab (Xgeva) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/denosumab-patient-drug-information Denosumab (Xgeva) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Antibody medications]] | ||
| + | [[Category:RANK ligand inhibitors]] | ||
Revision as of 21:18, 14 October 2012
Also known as Prolia.
General information
Class/mechanism: Human IgG2 monoclonal antibody that inhibits RANK ligand (RANKL). RANKL promotes the formation, function, and survival of osteoclasts, which are responsible for bone resorption.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Denosumab (Xgeva) patient drug information (Chemocare)[5]
- Brief patient counseling information can be found on page 13 of the Denosumab (Xgeva) package insert[1]
- Denosumab (Xgeva) patient drug information (UpToDate)[6]